High rates of adherence and treatment success in a public and public-private HIV clinic in India: potential benefits of standardized national care delivery systems

Anita Shet, Ayesha DeCosta, Elsa Heylen, Suresh Shastri, Sara Chandy, Maria Ekstrand, Anita Shet, Ayesha DeCosta, Elsa Heylen, Suresh Shastri, Sara Chandy, Maria Ekstrand

Abstract

Background: The massive scale-up of antiretroviral treatment (ART) access worldwide has brought tremendous benefit to populations affected by HIV/AIDS. Optimising HIV care in countries with diverse medical systems is critical; however data on best practices for HIV healthcare delivery in resource-constrained settings are limited. This study aimed to understand patient characteristics and treatment outcomes from different HIV healthcare settings in Bangalore, India.

Methods: Participants from public, private and public-private HIV healthcare settings were recruited between 2007 and 2009 and were administered structured interviews by trained staff. Self-reported adherence was measured using the visual analogue scale to capture adherence over the past month, and a history of treatment interruptions (defined as having missed medications for more than 48 hours in the past three months). In addition, CD4 count and viral load (VL) were measured; genotyping for drug resistance-associated mutations was performed on those who were in virological failure (VL > 1000 copies/ml).

Results: A total of 471 individuals were included in the analysis (263 from the public facility, 149 from the public-private facility and 59 from the private center). Private facility patients were more likely to be male, with higher education levels and incomes. More participants reported ≥ 95% adherence among public and public-private groups compared to private participants (public 97%; private 88%; public-private 93%, p < 0.05). Treatment interruptions were lowest among public participants (1%, 10%, 5% respectively, p < 0.001). Although longer clinic waiting times were experienced by more public participants (48%, compared to private 27%, public-private 19%, p < 0.001), adherence barriers were highest among private (31%) compared with public (10%) and public-private (17%, p < 0.001) participants. Viral load was detectable in 13% public, 22% private and 9% public-private participants (p < 0.05) suggesting fewer treatment failures among public and public-private settings. Drug resistance mutations were found more frequently among private facility patients (20%) compared to those from the public (9%) or public-private facility (8%, p < 0.05).

Conclusions: Adherence and treatment success was significantly higher among patients from public and public-private settings compared with patients from private facilities. These results suggest a possible benefit of the standardized care delivery system established in public and public-private health facilities where counselling by a multi-disciplinary team of workers is integral to provision of ART. Strengthening and increasing public-private partnerships can enhance the success of national ART programs.

References

    1. AIDS Epidemic update. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009.
    1. Address by Kofi Annan to the African Summit on HIV/AIDS, Tuberculosis and Other Infectious Diseases, Abuja, Nigeria. 2001. Accessed on 29 April 2011. 2001.
    1. National AIDS Control Organization, Annual Report, 2009-2010. Accessed on 26 April 2011.
    1. National AIDS Control Organization. Antiretroviral therapy guidelines for HIV infected adults and adolescents including post-exposure prophylaxis. Ministry of Health and Family Welfare, Government of India. 2007.
    1. De Costa A, Diwan V. 'Where is the public health sector?' Public and private sector healthcare provision in Madhya Pradesh, India. Health Policy. 2007;84(2-3):269–276. doi: 10.1016/j.healthpol.2007.04.004.
    1. Bajpai V, Saraya A. Healthcare financing: approaches and trends in India. Natl Med J India. pp. 231–235.
    1. Private Sector Utilization of HIV/AIDS Services & Health Expenditures by People Living with HIV/AIDS in India: Findings from Five High-Prevalence States. Private sector partnerships-one. United States Agency for International Development (USAID), Sept 2009. 2009.
    1. Private healthcare in developing countries: HIV/AIDS. 2008. Accessed on 28 April 2011.
    1. Ekstrand ML, Shet A, Chandy S, Singh G, Shamsundar R, Madhavan V, Saravanan S, Heylen E, Kumarasamy N. Suboptimal adherence associated with virologic failure and resistance mutations among patients on 1st line HAART in Bangalore, India. International Health. 2011;3:27–34. doi: 10.1016/j.inhe.2010.11.003.
    1. Ekstrand ML, Chandy S, Heylen E, Steward W, Singh G. Developing useful highly active antiretroviral therapy adherence measures for India: the Prerana study. J Acquir Immune Defic Syndr. 2010;53(3):415–416. doi: 10.1097/QAI.0b013e3181ba3e4e.
    1. Amico KR, Fisher WA, Cornman DH, Shuper PA, Redding CG, Konkle-Parker DJ, Barta W, Fisher JD. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr. 2006;42(4):455–459. doi: 10.1097/01.qai.0000225020.73760.c2.
    1. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5(2):74–79. doi: 10.1310/JFXH-G3X2-EYM6-D6UG.
    1. Balakrishnan P, Kumarasamy N, Kantor R, Solomon S, Vidya S, Mayer KH, Newstein M, Thyagarajan SP, Katzenstein D, Ramratnam B. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses. 2005;21(4):301–305. doi: 10.1089/aid.2005.21.301.
    1. Weiser S, Wolfe W, Bangsberg D, Thior I, Gilbert P, Makhema J, Kebaabetswe P, Dickenson D, Mompati K, Essex M. et al.Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):281–288. doi: 10.1097/00126334-200311010-00004.
    1. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, Shah R, Shao HJ, Morpeth SC, McNeill JD. et al.Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–1498. doi: 10.1086/522991.
    1. Shah B, Walshe L, Saple DG, Mehta SH, Ramnani JP, Kharkar RD, Bollinger RC, Gupta A. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis. 2007;44(9):1235–1244. doi: 10.1086/513429.
    1. Kumarasamy N, Safren SA, Raminani SR, Pickard R, James R, Krishnan AK, Solomon S, Mayer KH. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS. 2005;19(8):526–537. doi: 10.1089/apc.2005.19.526.
    1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C. et al.Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–824.
    1. Pradier C, Bentz L, Spire B, Tourette-Turgis C, Morin M, Souville M, Rebillon M, Fuzibet JG, Pesce A, Dellamonica P. et al.Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003;4(2):121–131. doi: 10.1310/BRBV-3941-H1PP-NDRY.
    1. Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou TA, Rourke SB, Glazier RH. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006;3:CD001442.
    1. National AIDS Control Programme, Phase III (2006-2011), Ministry of Health and Family Welfare, Government of India. 2006. Accessed on 26 April 2011.
    1. Operational guidelines for ART centers, National AIDS Control Organisation, Ministry of Health & Family Welfare, Government of India. 2007.
    1. UNGASS Country Progress Report: India. National AIDS Control Organization India (2010), New Delhi, India. 2010. Accessed on 20 April 2011.
    1. Bachani D, Garg R, Rewari BB, Hegg L, Rajasekaran S, Deshpande A, Emmanuel KV, Chan P, Rao KS. Two-year treatment outcomes of patients enrolled in India's national first-line antiretroviral therapy programme. Natl Med J India. pp. 7–12.
    1. Public-private partnerships for health: a review of best practices in the health sector, World Bank 2003. 2003. Accessed on 20 April 2011.
    1. Ghanashyam B. Can public-private partnerships improve health in India? Lancet. 2008;372(9642):878–879. doi: 10.1016/S0140-6736(08)61380-X.
    1. Asante AD, Zwi AB. Public-private partnerships and global health equity: prospects and challenges. Indian J Med Ethics. 2007;4(4):176–180.
    1. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill CJ, Cooper C. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):e438. doi: 10.1371/journal.pmed.0030438.
    1. Sarna A, Pujari S, Sengar AK, Garg R, Gupta I, Dam J. Adherence to antiretroviral therapy & its determinants amongst HIV patients in India. Indian J Med Res. 2008;127(1):28–36.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren